Metropolitan Life Insurance CO Oncocyte Corp Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.53 - $5.89 $82,012 - $136,842	-23,233 Closed	0 $0
Q2 2021 Jun 21, 2023	BUY	$3.77 - $6.0 $87,588 - $139,398	23,233 New	23,233 $133,000
Q2 2021 Mar 30, 2023	BUY	$3.77 - $6.0 $10,096 - $16,068	2,678 Added 13.03%	23,233 $133,000
Q2 2021 Aug 16, 2021	BUY	$3.77 - $6.0 $87,509 - $139,272	23,212 Added 110533.33%	23,233 $133,000
Q1 2021 Jun 26, 2023	BUY	$2.39 - $6.5 $49,126 - $133,607	20,555 New	20,555 $107 Million
Q1 2021 Mar 30, 2023	BUY	$2.39 - $6.5 $49,126 - $133,607	20,555 New	20,555 $106,000
Q1 2021 May 14, 2021	BUY	$2.39 - $6.5 $50 - $136	21 New	21 $107,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $404M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.